Abstract
Background Taenia solium is a tapeworm that causes taeniosis in humans and cysticercosis in humans and pigs. Within Eastern and Southern Africa (ESA), there are many countries in which information on the presence of human taeniosis and cysticercosis is missing. This systematic review aimed to describe the current information available and gaps in the epidemiology of human T. solium infections in ESA.
Methods/Principle Findings Scientific literature published between 1st January 2000 and 20th June 2022 in international databases [MEDLINE (Ovid), Embase (Ovid), Global Health (Ovid), Scopus (Elsevier), African Index Medicus (via WHO Global Index Medicus), and Open Grey] was systematically reviewed for ESA following the PRISMA approach. The study area included 27 countries that make up the ESA region. Information on either taeniosis, cysticercosis or NCC was available for 16 of 27 countries within the region. Most case reports for cysticercosis and NCC were from South Africa, while Tanzania had the most aggregated cysticercosis reports. Eleven countries reported on NCC with seven countries reporting data on NCC and epilepsy. Unconfirmed human T. solium taeniosis cases were reported in nine countries while two countries (Madagascar and Zambia) reported confirmed T. solium cases. The cysticercosis seroprevalence ranged between 0.99 - 40.8% on antigen (Ag) tests and between 1.7 - 45.3% on antibody (Ab) tests, while NCC- suggestive lesions on brain CT scans showed a prevalence range between 1.0 - 76%. The human taeniosis prevalence based on microscopy ranged between 0.1 - 14.7%. Based on Copro Ag- ELISA studies conducted in Kenya, Rwanda, Tanzania, and Zambia, the highest prevalence of 19.7% was reported in Kenya
Conclusions Despite the public health and economic impact of T. solium in ESA, there are still large gaps in knowledge about the occurrence of the parasite, and the resulting One Health disease complex, and monitoring of T. solium taeniosis and cysticercosis is mostly not in place
Author summary Taenia solium is a tapeworm that causes three diseases, taeniosis in humans and cysticercosis in humans and pigs. Neurocysticercosis, which occurs when the central nervous system is involved has been associated with up to 57% of epilepsy cases in sub–Saharan Africa. Diagnosing neurocysticercosis among people with epilepsy is vital to prevent further morbidity and mortality from the disease as well as to reduce the negative socio-cultural beliefs associated with epilepsy. Within Eastern and Southern Africa, there are many countries in which information on the presence of human taeniosis, cysticercosis and neurocysticercosis is missing. This systematic review aimed to describe the current information available and gaps in the epidemiology of human T. solium infections in Eastern and Southern Africa. We found that Information on either taeniosis, cysticercosis or NCC was available only for 16 of 27 countries within the region. We also found that most of the studies on T. solium taeniosis, cysticercosis and neurocysticercosis within the region have been done in Kenya, Madagascar, Mozambique, Rwanda, South Africa, Tanzania and Zambia. Understanding the epidemiology of T. solium infections is essential for monitoring, prevention and control of the disease complex in a One Health approach.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022343072
Funding Statement
This study was fully funded by the German Federal Ministry of Education and Research (BMBF) under CYSTINET-Africa 2018-Mar-002 and 01KA1618. The funder had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All references found eligible in our review are included in the supplementary materials (S2 Table).
